Cowen and Company Raises Agilent Technologies, Inc. (A) Price Target to $62.00
Agilent Technologies, Inc. (NYSE:A) had its price objective hoisted by Cowen and Company from $53.00 to $62.00 in a report released on Tuesday, May 23rd. The firm currently has a market perform rating on the medical research company’s stock.
A number of other brokerages have also recently weighed in on A. Jefferies Group LLC restated a buy rating and set a $59.00 price objective on shares of Agilent Technologies in a research note on Friday, March 17th. Deutsche Bank AG restated a buy rating and set a $58.00 price objective (up from $56.00) on shares of Agilent Technologies in a research note on Sunday, April 2nd. Zacks Investment Research upgraded Agilent Technologies from a hold rating to a buy rating and set a $63.00 price objective for the company in a research note on Tuesday, May 16th. Morgan Stanley upgraded Agilent Technologies from an equal weight rating to an overweight rating and set a $62.00 price objective for the company in a research note on Wednesday, March 15th. Finally, Janney Montgomery Scott upped their target price on Agilent Technologies from $55.00 to $60.00 and gave the company a buy rating in a research report on Monday, February 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Agilent Technologies currently has an average rating of Buy and an average target price of $59.31.
Agilent Technologies (A) traded up 0.51% during trading on Tuesday, reaching $59.51. The company’s stock had a trading volume of 2,157,514 shares. Agilent Technologies has a 12-month low of $41.98 and a 12-month high of $61.15. The firm’s 50-day moving average price is $58.04 and its 200 day moving average price is $51.94. The company has a market capitalization of $19.12 billion, a P/E ratio of 33.45 and a beta of 1.25.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 22nd. The medical research company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.10. The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 EPS. On average, analysts predict that Agilent Technologies will post $2.23 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be issued a dividend of $0.132 per share. This represents a $0.53 annualized dividend and a yield of 0.89%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s dividend payout ratio (DPR) is 29.78%.
In other Agilent Technologies news, CFO Didier Hirsch sold 5,710 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $60.60, for a total transaction of $346,026.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Patrick Kaltenbach sold 2,000 shares of the stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $52.90, for a total value of $105,800.00. Following the transaction, the insider now owns 42,132 shares in the company, valued at approximately $2,228,782.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 144,101 shares of company stock worth $8,410,449.
Several institutional investors have recently added to or reduced their stakes in A. Wells Fargo & Company MN increased its position in Agilent Technologies by 0.5% in the third quarter. Wells Fargo & Company MN now owns 1,424,764 shares of the medical research company’s stock valued at $67,093,000 after buying an additional 6,539 shares during the period. Huntington National Bank increased its position in Agilent Technologies by 902.0% in the third quarter. Huntington National Bank now owns 10,190 shares of the medical research company’s stock valued at $480,000 after buying an additional 9,173 shares during the period. Stratos Wealth Partners LTD. increased its position in Agilent Technologies by 38.8% in the third quarter. Stratos Wealth Partners LTD. now owns 14,377 shares of the medical research company’s stock valued at $677,000 after buying an additional 4,021 shares during the period. WealthTrust Fairport LLC increased its position in Agilent Technologies by 4.3% in the third quarter. WealthTrust Fairport LLC now owns 101,938 shares of the medical research company’s stock valued at $4,800,000 after buying an additional 4,249 shares during the period. Finally, Decatur Capital Management Inc. purchased a new position in Agilent Technologies during the third quarter valued at $7,285,000.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Stock Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related stocks with our FREE daily email newsletter.